RxDoctor Payments Data

Michael McCormack, MD

Medical Oncology · Hagerstown, MDNPI 1821018821

Payments from drug & device makers

$100,979in general payments, 2019–2025

Across 28 payments — averaging $3606.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$75K
  • Amgen$18K
  • Pfizer$6K
  • AstraZeneca$2K
  • AbbVie$218
  • E.r. Squibb & Sons, L.L.C.$117
  • plus $57 from 3 others
$7,397in research payments, 2019–2025

Across 2 payments — averaging $3698.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K

What the payments were for

  • Consulting fees$1,66576%
  • Food & beverage$48022%
  • Education$502%

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly10$75,165
Amgen5$17,748
Pfizer3$5,877
AstraZeneca3$1,797
AbbVie3$218
E.r. Squibb & Sons, L.L.C.1$117
Takeda Pharmaceuticals U.S.A., Inc.1$33
Fortovia Therapeutics, Inc.1$12
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,979 in reported general payments places this provider in the 45th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$30,587
Medicare patients
167
Services billed
380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →